Eddingpharm adds another licensed in candidate to oncology pipeline
This article was originally published in Scrip
Chinese pharma enterprises are continuing to gain access to novel product candidates through licensing deals with foreign partners, Hong Kong-based Eddingpharm becoming the latest to strike a deal with a Western firm just a month after its previous tie-up.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.